Fostering optimal recovery through creatine supplementation and electrical muscular stimulation

Fostering optimal recovery through creatine supplementation and electrical muscular stimulation - FORCE

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00035357

Enrollment

Registered

2024-11-12

Start date

2025-03-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G72.8

Interventions

Group 1: Control (medical nutrition therapy following local SOP) Group 2: Electrical muscle stimulation (10 days, rectus femoris muscle) Group 3: Creatine supplementation (90 days, 5g/die) Group 4: El

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: • pmRS 0-3 • Frailty Scale 10 days

Exclusion criteria

Exclusion criteria: • Myopathies • Rhabdomyolysis (CK > 2000 U/L) • Mitochondriopathies • Diseases of the second motor neuron • Neuromuscular transmission disorders • Pacemaker or other stimulation procedures • Epilepsy or status epilepticus

Design outcomes

Primary

Measure	Time frame
Decrease in muscle thickness of MRF (M. rectus femoris) on day 10 (+/-1) after admission to the intensive care unit	—

Secondary

Measure	Time frame
• Heckmatt score/Grayscale homogeneity @ day 10 (+/- 1) • EQ-5D-5L @ day 90 (+/- 14 days) • PCS - SF36 @ day 90 (+/- 14 days) • GOSE @ day 90 (+/- 14 days) • GOSE @ ICU discharge • Hand grip @ ICU discharge • MRC-SS @ ICU discharge • Days to discharge alive from ICU • Duration of invasive ventilation (hours) • Decrease in volume (ultrasound-based) of stimulated muscle (MRF) @ day 5 (+/-1) and day 10 (+/-1) • Decrease in volume + thickness (ultrasound-based) of non-stimulated muscle (TBA (M. tibialis anterior) and TM (M. temporalis)) @ day 5 (+/-1) and day 10 (+/-1) • GFR (Cystatin C-based) d0, d10 • Continuous renal replacement therapy (yes/no) • Clinically relevant fluid overload (yes/no) • Delirium (days with delirium according to ISDSC relative to total ICU stay) • Cumulative fluid balance @ ICU discharge • New hemodynamically relevant cardiac arrhythmias (yes/no)	—

Measure

Time frame

• Heckmatt score/Grayscale homogeneity @ day 10 (+/- 1) • EQ-5D-5L @ day 90 (+/- 14 days) • PCS - SF36 @ day 90 (+/- 14 days) • GOSE @ day 90 (+/- 14 days) • GOSE @ ICU discharge • Hand grip @ ICU discharge • MRC-SS @ ICU discharge • Days to discharge alive from ICU • Duration of invasive ventilation (hours) • Decrease in volume (ultrasound-based) of stimulated muscle (MRF) @ day 5 (+/-1) and day 10 (+/-1) • Decrease in volume + thickness (ultrasound-based) of non-stimulated muscle (TBA (M. tibialis anterior) and TM (M. temporalis)) @ day 5 (+/-1) and day 10 (+/-1) • GFR (Cystatin C-based) d0, d10 • Continuous renal replacement therapy (yes/no) • Clinically relevant fluid overload (yes/no) • Delirium (days with delirium according to ISDSC relative to total ICU stay) • Cumulative fluid balance @ ICU discharge • New hemodynamically relevant cardiac arrhythmias (yes/no)

—

Countries

Germany

Contacts

Public ContactMoritz Schmidbauer

LMU Klinikum

moritz.schmidbauer@med.uni-muenchen.de+49 89 4400 0

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026